Friday 6 November 2026 Export SMMT’s income statement to Excel — free account

Summit Therapeutics PLC

SMMT Healthcare Biotechnology

Summit Therapeutics PLC’s revenue for fiscal 2022 (year ended December 2022) was $705,000.00.

EPS: +63.2%
Free cash flow: −112.8%

Quarter to June 2026, against a year earlier

Insider buying

16.13 1.94 +13.67%

Follow SMMT

Alert me

Market cap: $11.3B
P/E: 0.0×
Fwd P/E: 0.0×
Dividend yield: —
F-score: 3/9
Altman Z: 0.88
Beneish M: −5.00
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Summit Therapeutics PLC 10-Q filed Nov 4, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed Nov 4, 2026 · accepted 5:08 PM ET · Document on sec.gov · Filing index

Red flags

Short cash runway Nov 4, 2026
Summit Therapeutics PLC’s cash and short-term investments cover about 1.1 quarters of its operating cash burn

10-Q filed Nov 4, 2026 · The filing · sec.gov
Share dilution Nov 4, 2026
Shares outstanding rose 7.4% in a year, to 799.8 million

10-Q filed Nov 4, 2026 · The filing · sec.gov

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Oct 20, 2025: 49 added · 26 removed · 53 modified; 6 with only figures updated; 2 moved without change

Summit Therapeutics PLC 10-Q filed Nov 4, 2026

Red flags

What changed

Stockrow Weekly